🔗 Share this article

Given that America continues making sweeping revisions to its immunization recommendations, an unexpected name appears unexpectedly: Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations in the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Health officials had intended to announce major revisions to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for public health gain. The planned update has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting some pediatric shot schedules in the US to become more in line with Denmark, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – usually the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Former heads of the center would “understand laws and regulations and the underlying principles of drug development”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that former directors who ran CBER have had.”

This division has an immense workload at the agency, Woodcock stated.

“The public just zeroes in on the novel medication approvals, but the generic program clears a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these need to be managed,” Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative element to the job, which manages more than 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” the former official said.

Response and Controversial Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among agency officials on vaccines, a representative responded that the “questions are based on inaccurate presumptions”.

“Her resume aligns with the duties of her position,” the spokesperson stated, noting the months Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg inherits the agency head's controversial expedited review system, a controversial rapid medication authorization process that reportedly troubled her former heads. “How are these medications being chosen for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he said, “the FDA looks to be trending towards laxer oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if concerning, history, critics have noted. She authored a study using unconfirmed crowd-sourced reports to assess the incidence of myocarditis after COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the current administration included altering guidelines for recently developed shots and halting “non-essential” vaccines, she said following the vote on a online show. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from receiving COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her conclusions and tailors the evidence to accommodate the evidence in a highly disingenuous, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg joined other skeptics, {like|